Syner-G BioPharma Group

Syner-G BioPharma Group is a leading company in the biotechnology and pharmaceutical industries, offering comprehensive expertise in Chemistry, Manufacturing, and Controls (CMC), which they term as CMC 360™. They also specialize in providing medical writing services, covering a broad range of therapeutic areas and all phases of development. The company supports clients with global regulatory strategic plans, agency meeting assistance, and electronic submissions. Established in 2007, the United States-based company received a Private Equity Round investment in 29 October 2020 from Riverside Partners.

Their commitment to enhancing human health and inspiring excellence among colleagues is reflected in their slogan, "#weinspire". Syner-G BioPharma Group's extensive experience spans various product types, including small molecules, monoclonal antibodies, and cell and gene therapy products.

With a strong focus on regulatory compliance and high-quality standards, the company positions itself as a crucial partner in navigating the complexities of development challenges and regulatory filing pathways. By offering in-depth expertise and a commitment to excellence, Syner-G BioPharma Group stands out as a formidable player in the biopharmaceutical sector.